Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 8, 2009, Pages 752-759

  Verbruggen, Bert ^a   Van Heerde, Waander L ^a   Laros Van Gorkom, Britta A P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bethesda assay; Factor VIII; Hemophilia; Inhibitors; Nijmegen assay

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; EPITOPE; LUPUS ANTICOAGULANT; NEUTRALIZING ANTIBODY; VON WILLEBRAND FACTOR;

ASSAY; BETHESDA ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; HUMAN; NIJMEGEN ASSAY; PARTIAL THROMBOPLASTIN TIME; PH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; LUPUS COAGULATION INHIBITOR; QUALITY ASSURANCE, HEALTH CARE;

EID: 77449158821     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1245107     Document Type: Review

References (43)

1. Margolius A Jr, Jackson D P., Ratnoff O D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 1961 40 145-202
2. Algiman M, Dietrich G, Nydegger U E., Boieldieu D, Sultan Y, Kazatchkine M D. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 1992 89 (9) 3795-3799
3. Lutz H U., Binder C J., Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009 30 (1) 43-51
4. Lawrence J S., Johnson J B. The presence of a circulating anticoagulant in a male member of a hemophiliac family. Trans Am Clin Climatol Assoc 1941 57 223-231
5. Biggs R, Macfarlane R G. Human blood coagulation and its disorders. 2nd ed. Oxford, United Kingdom Blackwell Scientific Publications 1962
6. Biggs R, Bidwell E. A method for the study of antihaemophilic globulin inhibitors with reference to six cases. Br J Haematol 1959 5 379-395
7. Biggs R, Austen D E., Denson K W., Rizza C R., Borrett R. The mode of action of antibodies which destroy factor VIII. I. Antibodies which have second-order concentration graphs. Br J Haematol 1972 23 (2) 125-135
8. Kasper C, Aledort L, Counts R et al. Letter: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975 34 (3) 869-872
9. Rosendaal F R., Nieuwenhuis H K., van den Berg H M., Heijboer H, Mauser-Bunschoten E P., van der Meer J, Smit C, Strengers P F., Brit E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993 81 (8) 2180-2186
10. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995 73 (2) 247-251
11. Giles A R., Verbruggen B, Rivard G E., Teitel J, Walker I, Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost 1998 79 (4) 872-875
12. Charles R M., Brown S, Collins P W., Keeling D M., Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization. Br J Haematol 2006 133 591-605
13. Brandt J T., Barna L K., Triplett D A. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995 74 (6) 1597-1603
14. Gawryl M S., Hoyer L W. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982 60 (5) 1103-1109
15. Berntorp E, Ekman M, Gunnarsson M, Nilsson I M. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996 2 95-99
16. Astermark J, Voorberg J, Lenk H et al. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia 2003 9 (5) 567-572
17. Martin P G., Sukhu K, Chambers E, Giangrande P L. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. Clin Lab Haematol 1999 21 (2) 125-128
18. Regnault V, Stoltz J F. Quantitation of factor VIII antibodies by an enzyme-linked immunoassay method. Blood 1994 83 (4) 1155-1156
19. Mondorf W, Klinge J, Luban N L., Bray G, Saenko E, Scandella D, Recombinate PUP Study Group. Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay. Haemophilia 2001 7 (1) 13-19
20. Dazzi F, Tison T, Vianello F et al. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996 93 (3) 688-693
21. Sahud M A., Pratt K P., Zhukov O, Qu K, Thompson A R. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007 13 (3) 317-322
22. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novkov I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost 2001 86 (6) 1435-1439
23. Verbruggen B, van Heerde W, Novkov I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002 88 (2) 362-364
24. van Den Brink E N., Turenhout E A., Davies J et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000 95 (2) 558-563
25. Triplett D A. Simultaneous occurrence of lupus anticoagulant and factor VIII inhibitors. Am J Hematol 1997 56 (3) 195-196
26. Blanco A N., Cardozo M A., Candela M, Santarelli M T., Pérez Bianco R, Lazzari M A. Anti-factor VIII inhibitors and lupus anticoagulants in haemophilia A patients. Thromb Haemost 1997 77 (4) 656-659
27. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001 86 (1) 83-91
28. Tripodi A, Mancuso M E., Chantarangkul V et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005 51 (10) 1883-1885
29. Cohen H, Mackie I J., Anagnostopoulos N, Savage G F., Machin S J. Lupus anticoagulant, anticardiolipin antibodies, and human immunodeficiency virus in haemophilia. J Clin Pathol 1989 42 (6) 629-633
30. al-Saeed A, Makris M, Malia R G., Preston F E., Greaves M. The development of antiphospholipid antibodies in haemophilia is linked to infection with hepatitis C. Br J Haematol 1994 88 (4) 845-848
31. Kazmi M A., Pickering W, Smith M P., Holland L J., Savidge G F. Acquired haemophilia A: errors in the diagnosis. Blood Coagul Fibrinolysis 1998 9 (7) 623-628
32. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2009 February 18 (Epub ahead of print)
33. Chantarangkul V, Tripodi A, Arbini A, Mannucci P M. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992 67 (4) 355-365
34. Triplett D A., Barna L K., Unger G A. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993 70 (5) 787-793
35. Exner T. Diagnostic methodologies for circulating anticoagulants. Thromb Haemost 1995 74 (1) 338-344
36. Blanco A N., Alcira Peirano A, Grosso S H., Gennari L C., Pérez Bianco R, Lazzari M A. A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant. Haematologica 2002 87 (3) 271-278
37. Chandler W L., Ferrell C, Lee J, Tun T, Kha H. Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol 2003 120 (1) 34-39
38. Ling M, Duncan E M., Rodgers S E. et al. Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Br J Haematol 2001 114 (4) 861-867
39. Prescott R, Nakai H, Saenko E L. et al, Recombinate and Kogenate Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 1997 89 (10) 3663-3671
40. Salvagno G L., Astermark J, Ekman M et al. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia 2007 13 (1) 51-56
41. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment programme of the ECAT Foundation. Semin Thromb Hemost 2009 35 (8) xxx-xxx
42. Kitchen S, Jennings I, Preston F E., Kitchen D P., Woods T AL, Walker I D. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK NEQAS for blood coagulation. Semin Thromb Hemost 2009 35 (8) xxx-xxx
43. Favaloro E J., Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009 35 (8) xxx-xxx